Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
nab-Sirolimus + Endocrine Therapy in HR+/HER2- Advanced Breast Cancer
NCT06957379Phase 2Active, not recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Feb 2024
- Primary completion
- Jun 2025
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nab-sirolimus in breast cancer, sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoint: Objective Response Rate. Started Feb 2024; status: active, not recruiting.
02
Drugs
nab-sirolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06957379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06957379.